1. What Is the Myeloma Drug Market?
The Myeloma Drug Market covers the systemic therapies used to treat multiple myeloma from the newly diagnosed transplant-eligible and transplant-ineligible patient through the relapsed and refractory disease. The relapsed and refractory disease requires the sequential treatment with the available drug classes. The market spans the proteasome inhibitors bortezomib, carfilzomib, and ixazomib, the immunomodulatory drugs thalidomide, lenalidomide, and pomalidomide, and the CD38 antibodies daratumumab and isatuximab. The BCMA-targeted bispecific antibodies teclistamab, elranatamab, and linvoseltamab, the BCMA ADC belantamab mafodotin, and the CAR-T cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel complete the treatment classes. Multiple myeloma drug development has progressed from the thalidomide and bortezomib era of modest improvements through the lenalidomide plus dexamethasone maintenance that extended the progression-free survival. The current quadruplet induction regimen with daratumumab-VRd achieves the MRD-negative complete response in over 60 percent of newly diagnosed transplant-eligible patients in the GRIFFIN trial. The myeloma drug market is being reshaped by the BCMA-targeting bispecific antibody teclistamab demonstrating 63 percent overall response rate in the MajesTEC-1 trial for the penta-refractory myeloma. The penta-refractory myeloma has failed the proteasome inhibitor, the immunomodulatory drug, the CD38 antibody, the BCMA ADC, and the CAR-T cell therapy. The bispecific T cell engager provides the off-the-shelf cellular immunotherapy that the exhausted myeloma patient can access without the delay of personalised manufacturing.
2. Myeloma Drug Market Size & Forecast
3. Emerging Technologies
- Daratumumab quadruplet DARA-VRd induction GRIFFIN and MASTER Phase II trials demonstrated 60 to 80 percent MRD negativity in the newly diagnosed transplant-eligible multiple myeloma patients receiving the CD38 antibody plus bortezomib-lenalidomide-dexamethasone combination. This establishes the MRD-guided treatment concept where the MRD-negative status after induction guides the consolidation and maintenance decisions. The treatment de-escalates in the MRD-negative patient and escalates in the MRD-positive patient based on the molecular response depth.
- BCMA CAR-T cell therapy idecabtagene vicleucel Abecma KarMMa-3 trial demonstrated 13.3-month PFS versus 4.4-month conventional triplet regimen in the relapsed myeloma after 2 to 4 prior lines. The CAR-T is now the preferred treatment before the exhaustion of the available drug classes. The earlier-line use in the KarMMa-3 population applies the cellular therapy to the patients most likely to benefit from the deep response.
- Ciltacabtagene autoleucel CARTITUDE-4 Phase III demonstrated 29-month PFS versus 12-month standard care triplet in the 1 to 3 prior line relapsed myeloma. The earlier-line BCMA CAR-T use is now the preferred approach. The approach precedes the penta-refractory disease state that the MajesTEC-1 teclistamab trial enrolled.
- Teclistamab BCMA bispecific T cell engager MajesTEC-1 trial achieved 63 percent ORR in the penta-refractory myeloma with the 18-month duration of response for the responders. The durable disease control comes from the weekly subcutaneous injection. The patient-specific CAR-T manufacturing cannot serve the urgent access that the penta-refractory disease requires, which the off-the-shelf bispecific provides.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Immunotherapy Market.
4. Key Market Opportunity
Material revenue potential in the Myeloma Drug market is moving BCMA-targeted CAR-T and bispecific therapy to earlier treatment lines, where demonstrating benefit before heavy pretreatment creates a larger addressable population at earlier stages. Companies with early-line CAR-T or bispecific data in myeloma capture this major commercial opportunity. Adjacent demand centers on quadruplet frontline therapy adding novel mechanism to daratumumab-VRd. As earlier-line BCMA targeting advances and quadruplet frontline data matures, the addressable opportunity is expanding from heavily pretreated relapsed disease toward first and second-line myeloma with novel immune therapies.
5. Top Companies in the Myeloma Drug Market
The following organisations hold leading positions in the Myeloma Drug Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Johnson and Johnson
- Bristol-Myers Squibb
- Sanofi
- Amgen
- Takeda
- GSK
- Pfizer
- AbbVie
- Regeneron
- Karyopharm Therapeutics
- Roche
- Legend Biotech
- Pharma Mar
6. Market Segmentation
The Myeloma Drug Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Class | PI IMiD Anti-CD38 CAR-T Bispecific Antibody BCMA Antibody |
| By Line | First-Line Second-Line Relapsed/Refractory |
| By Transplant Eligibility | Eligible Ineligible |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Myeloma Drug Market trajectory over the forecast period:
Daratumumab Quadruplet DARA-VRd Achieving 60 to 80 Percent MRD Negativity in Newly Diagnosed Transplant-Eligible Myeloma Has Established the MRD-Guided Treatment Strategy Where MRD Status After Induction Drives De-Escalation or Escalation Decisions.Johnson and Johnson's Tecvayli demonstrated 62% overall response rate in the MajesTEC-1 trial in patients who had received a median of five prior lines of therapy including anti-CD38 antibody, IMiD, and proteasome inhibitor, with 20% of patients achieving complete response. The 1.5 mg/kg weekly subcutaneous dosing schedule is administered in outpatient settings after step-up dosing, making BCMA bispecific therapy accessible to patients at community cancer centres without CAR-T apheresis and infusion infrastructure. MajesTEC-1 results directly prompted the clinical development of combinations with lenalidomide and bortezomib in earlier myeloma lines where bispecific therapy could prevent the triple-class refractoriness that defines the patients most in need.
Ciltacabtagene Autoleucel CARTITUDE-4 29-Month PFS Versus 12-Month Standard Care in 1 to 3 Prior Line Relapsed Myeloma Has Established Earlier-Line BCMA CAR-T as the Preferred Approach Before the Penta-Refractory State That Depletes the Available Drug Classes.Bristol-Myers Squibb's Abecma in KarMMa-3 and Johnson and Johnson's Carvykti in CARTITUDE-4 both demonstrated superior progression-free survival versus standard two to three drug regimens in triple-class-exposed relapsed myeloma, establishing that CAR-T benefit extends to patients who are not yet triple-class refractory. The CARTITUDE-4 hazard ratio of 0.26 for progression-free survival versus carfilzomib-based therapy represented one of the most dramatic efficacy signals in myeloma trial history, and the two-year event-free survival rate above 60% for Carvykti in this setting provides a benchmark that competing cell therapies will need to meet or exceed. The manufacturing bottleneck remains the principal constraint on commercial penetration, as median vein-to-vein time of four to five weeks for autologous CAR-T creates clinical urgency risk in quickly progressing patients.
Teclistamab BCMA Bispecific 63 Percent ORR in Penta-Refractory Myeloma With 18-Month Response Duration From Weekly Subcutaneous Injection Provides the Urgent Off-the-Shelf Cellular Immunotherapy That Patient-Specific CAR-T Manufacturing Cannot Serve at the Required Access Speed.GSK's belantamab targeting BCMA with an MMAF payload received accelerated approval, withdrawal, and reapproval in a sequence driven by the ocular toxicity managed through mandatory corneal monitoring in the BLENREP programme. DREAMM-3 demonstrated superiority over pomalidomide-dexamethasone, and DREAMM-7 and DREAMM-8 combination data with bortezomib-dexamethasone and pomalidomide-bortezomib-dexamethasone established belantamab as a combination partner that outperforms backbone regimens without it. The lesson from belantamab's regulatory journey is that corneal monitoring can be integrated into myeloma practice when oncologists are trained and when the clinical benefit is clear, providing a template for managing ocular toxicity in future ADC programmes with similar mechanisms.
For related market intelligence, see the Oncology Drug Market.
8. Segmental Analysis
By drug class, the immunomodulatory and proteasome inhibitor segment dominated the Myeloma Drug Market in 2025, as Bristol-Myers Squibb's Revlimid and Pomalyst and Takeda's Velcade backbone anchored frontline and maintenance regimens, generating the largest revenue pool in the disease.
By line of therapy, the relapsed and refractory segment is projected to register the highest growth rate through 2034, as Johnson and Johnson's Tecvayli bispecific and Carvykti CAR-T and Bristol-Myers Squibb's Abecma move into earlier treatment lines and expand the addressable population.
9. Regional Analysis
Regional demand patterns across the Myeloma Drug Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Myeloma Drug Market in 2025, accounting for approximately 44% of global revenue, attributed to US premium pricing for daratumumab combinations, BCMA CAR-T therapies, and bispecific antibodies and the concentration of Johnson and Johnson, Bristol-Myers Squibb, and GSK commercial operations. Moreover, CAR-T and bispecific adoption in myeloma are most advanced in US haematology. In addition, lenalidomide maintenance sustains the large myeloma patient treatment base. Regional dominance is due to this combination of pricing environment and innovative therapy adoption.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Myeloma Drug Market through 2034, driven by expanding daratumumab combination access and BCMA bispecific adoption across European healthcare systems and the large myeloma patient population. The region is also witnessing CAR-T myeloma access growing with infrastructure development. Moreover, lenalidomide and proteasome inhibitor combinations sustain treatment volume. The combination of these demand drivers and access expansion positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Myeloma Drug Market was valued at USD 25.42 Bn in 2025 and is projected to reach USD 66.09 Bn by 2034, growing at a CAGR of 11.2% over the 2026–2034 forecast period.
The Myeloma Drug Market is projected to grow at a CAGR of 11.2% from 2026 to 2034.
North America dominated the Myeloma Drug Market in 2025, accounting for approximately 44% of global revenue, attributed to US premium pricing for daratumumab combinations, BCMA CAR-T therapies, and bispecific antibodies and the concentration of Johnson and Johnson, Bristol-Myers Squibb, and GSK commercial operations.
The leading companies in the Myeloma Drug Market include Johnson and Johnson, Bristol-Myers Squibb, Sanofi, Amgen, Takeda, GSK, Pfizer, AbbVie, Regeneron, Karyopharm Therapeutics, Roche, Legend Biotech, Pharma Mar.
Daratumumab quadruplet dara-vrd achieving 60 to 80 percent mrd negativity in newly diagnosed transplant-eligible myeloma has established the mrd-guided treatment strategy where mrd status after induction drives de-escalation or escalation decisions.
By drug class, the immunomodulatory and proteasome inhibitor segment dominated the Myeloma Drug Market in 2025, as Bristol-Myers Squibb's Revlimid and Pomalyst and Takeda's Velcade backbone anchored frontline and maintenance regimens, generating the largest revenue pool in the disease.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.